Spero Therapeutics, Inc.

As of March 27, 2025, Spero Therapeutics, Inc. is considered overvalued with a risky valuation grade due to its high Price to Book Value of 4.13, negative EV to EBIT and EV to EBITDA ratios, and a low Return on Equity of -203.20%, despite a strong year-to-date stock return of 94.17%.

As of March 27, 2025, Spero Therapeutics, Inc. is considered overvalued with a risky valuation grade due to negative financial metrics, including a Price to Book Value of 4.13 and an ROE of -203.20%, despite a strong year-to-date stock performance of 184.47%.

As of June 11, 2025, the trend is bullish with moderate strength, supported by a bullish MACD, moving averages, and OBV, although bearish RSI readings suggest potential weakness.

As of March 2022, the management team of Spero Therapeutics, Inc. includes Dr. Milind Deshpande (Independent Chairman), Dr. Ankit Mahadevia (President and CEO), and several Independent Directors: Dr. Jean-Francois Formela, Mr. Scott Jackson, Mr. John Pottage, Ms. Cynthia Smith, and Mr. Frank Thomas. They oversee the company's strategic direction and governance.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections. As of March 2025, it reported net sales of $5 million and a net loss of $14 million, with a market cap of $162.14 million.

As of Jun 18, Spero Therapeutics, Inc. has a market capitalization of 162.14 million and reported net sales of 28.31 million with a net profit of -69.77 million over the latest four quarters.